Click here to view online. Add this email to your safelist.

AstraZeneca logo

AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018

20 August 2018

AstraZeneca and MedImmune, its global biologics research and development arm, will present new data from its Cardiovascular, Renal and Metabolism (CVRM) portfolio of medicines at the European Society of Cardiology (ESC) Congress in Munich, Germany, 25-29 August 2018, aiming to help inform clinical practice for the treatment of patients with overlapping CVRM diseases and multiple risk factors.

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2018

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.